Baliopharm Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Latest Deal Type
-
2ndary - Private
Baliopharm General Information
Description
Developer of antibody-derived therapeutics designed to treat chronic liver diseases, immune-mediated inflammatory diseases, and cancer. The company offers monoclonal antibodies, monovalent formats, and bispecifics, enabling healthcare organizations to address acute and chronic conditions with increased target selectivity and enhanced safety profiles.
Contact Information
Website
www.baliopharm.de(Operating Subsidiary)
Corporate Office
- Pfeffingerstrasse 19
- Reinach
- 4153 Basel
- Switzerland
Corporate Office
- Pfeffingerstrasse 19
- Reinach
- 4153 Basel
- Switzerland
Baliopharm Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 2. Later Stage VC | 01-Jan-2021 | Completed | Generating Revenue | |||
| 1. Merger/Acquisition | 10-Apr-2018 | Completed | Generating Revenue |
Baliopharm Comparisons
Industry
Financing
Details
Baliopharm Competitors (49)
One of Baliopharm’s 49 competitors is AnTolRx, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| CuraVac | Formerly Accelerator/Incubator backed | Rixensart, Belgium | ||||
| Agomab Therapeutics | Formerly VC-backed | Antwerp, Belgium | ||||
| Verona Pharma | Corporate Backed or Acquired | London, United Kingdom | ||||
| Xenikos | Venture Capital-Backed | Nijmegen, Netherlands |
Baliopharm Patents
Baliopharm Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2018371232-A1 | Anti-hutnfr1 therapy of nonalcoholic steatohepatitis | Active | 27-Nov-2017 | ||
| AU-2018371232-B2 | Anti-hutnfr1 therapy of nonalcoholic steatohepatitis | Active | 27-Nov-2017 | ||
| AU-2018371232-B9 | Anti-hutnfr1 therapy of nonalcoholic steatohepatitis | Active | 27-Nov-2017 | ||
| CA-3081493-A1 | Anti-hutnfr1 therapy of nonalcoholic steatohepatitis | Pending | 27-Nov-2017 | ||
| EP-3717068-A1 | Anti-hutnfr1 therapy of nonalcoholic steatohepatitis | Pending | 27-Nov-2017 | A61P1/16 |
Baliopharm Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Xlife Sciences | Venture Capital | Minority |
Baliopharm Investments (1)
Baliopharm’s most recent deal was a Seed Round with 3Z for . The deal was made on 05-Jul-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 3Z | 05-Jul-2016 | Seed Round | Drug Discovery |
Baliopharm FAQs
-
When was Baliopharm founded?
Baliopharm was founded in 2006.
-
Where is Baliopharm headquartered?
Baliopharm is headquartered in Basel, Switzerland.
-
What industry is Baliopharm in?
Baliopharm’s primary industry is Drug Discovery.
-
Is Baliopharm a private or public company?
Baliopharm is a Private company.
-
What is Baliopharm’s current revenue?
The current revenue for Baliopharm is .
-
Who are Baliopharm’s investors?
Xlife Sciences has invested in Baliopharm.
-
Who are Baliopharm’s competitors?
AnTolRx, CuraVac, Agomab Therapeutics, Verona Pharma, and Xenikos are some of the 49 competitors of Baliopharm.
-
Who acquired Baliopharm?
Baliopharm was acquired by Cellaion.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process